Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xen2174 intrathecal single ascending dose interaction study with bupivacaine in healthy volunteers
NL-OMON35341Withdrawn
- Sponsor
- Xenome Ltd
- Start
- Aug 2011
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Randomised, double-blind trial of Xen2174 and bupivacaine in postoperative pain (8 arms), sponsored by Xenome Ltd. Primary endpoints: Pressure pain threshold and tolerance, Electrical pain threshold and tolerance single stimulus and 10 more. Planned start Aug 2011; status: withdrawn.
02
Drugs
Xen2174bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NL-OMON35341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35341.